Insulet Corp. closed 7.87% below its 52-week high of $289.46, which the company achieved on February 7th.

Insulet (NASDAQ:PODD – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research ...

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Insulet in a research note ...

Bernstein raised the firm’s price target on Insulet (PODD) to $335 from $315 following a strong quarter and an “impressive” outside-U.S.

Investors eyeing a purchase of Insulet Corp (Symbol: PODD) stock, but cautious about paying the going market price of $285.98/share, might benefit from considering selling puts among the ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Feb 20(Reuters) - Insulet (PODD.O), opens new tab reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps. The company ...

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...